In addition, the use of a γ-secretase inhibitor led to the loss of ER-α and GATA-3 expression as well as an observed increase in the expression of proliferation markers (CXCL1) and basal-like breast cancer markers (p-cadherin, CTPS1 and FOXC1) [Figure 6D (iii)]. The gene discussed is FOXC1; the disease is breast carcinoma.